Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Opus Genetics (IRD) Short-Term Debt repayments (2021 - 2022)

Opus Genetics has reported Short-Term Debt repayments over the past 2 years, most recently at $215000.0 for Q2 2022.

Quarterly Short-Term Debt repayments changed N/A to $215000.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $215000.0 through Mar 2023, down 50.12% year-over-year, with the annual reading at $538000.0 for FY2022, 398.15% up from the prior year.
Short-Term Debt repayments was $215000.0 for Q2 2022 at Opus Genetics, down from $323000.0 in the prior quarter.
Over five years, Short-Term Debt repayments peaked at $323000.0 in Q1 2022 and troughed at $108000.0 in Q4 2021.